- Home
- GECC vs BDSX Comparison
GECC vs BDSX Comparison
Compare GECC & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- BDSX
- Stock Information
- Founded
- GECC 2016
- BDSX 2005
- Country
- GECC United States
- BDSX United States
- Employees
- GECC N/A
- BDSX N/A
- Industry
- GECC Finance: Consumer Services
- BDSX Precision Instruments
- Sector
- GECC Finance
- BDSX Health Care
- Exchange
- GECC Nasdaq
- BDSX Nasdaq
- Market Cap
- GECC 122.4M
- BDSX 115.4M
- IPO Year
- GECC N/A
- BDSX 2020
- Fundamental
- Price
- GECC $10.50
- BDSX $0.26
- Analyst Decision
- GECC
- BDSX Strong Buy
- Analyst Count
- GECC 0
- BDSX 5
- Target Price
- GECC N/A
- BDSX $1.75
- AVG Volume (30 Days)
- GECC 20.2K
- BDSX 2.9M
- Earning Date
- GECC 07-31-2025
- BDSX 08-06-2025
- Dividend Yield
- GECC 14.07%
- BDSX N/A
- EPS Growth
- GECC N/A
- BDSX N/A
- EPS
- GECC 0.42
- BDSX N/A
- Revenue
- GECC $42,909,000.00
- BDSX $74,463,000.00
- Revenue This Year
- GECC $32.54
- BDSX $17.29
- Revenue Next Year
- GECC N/A
- BDSX $29.33
- P/E Ratio
- GECC $25.06
- BDSX N/A
- Revenue Growth
- GECC 18.13
- BDSX 35.76
- 52 Week Low
- GECC $8.87
- BDSX $0.17
- 52 Week High
- GECC $11.39
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- GECC 46.09
- BDSX 38.93
- Support Level
- GECC $10.90
- BDSX $0.27
- Resistance Level
- GECC $10.62
- BDSX $0.33
- Average True Range (ATR)
- GECC 0.22
- BDSX 0.03
- MACD
- GECC -0.06
- BDSX 0.01
- Stochastic Oscillator
- GECC 25.53
- BDSX 19.54
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.